Find disease awareness content and relevant supporting materials

Follow all the latest developments with daily highlights from the European Society of Medical Oncology Breast Cancer Congress in Berlin, Germany, 3–5 May 2022.

For the first time ever in a human, doctors have performed coronary artery bypass grafting without having to cut through the patient's chest, similar to how many aortic valve replacement procedures are now done.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Keytruda (pembrolizumab) from Merck Sharp & Dohme for triple negative breast cancer.

Join Professor Nadia Harbeck, Director of the Breast Centre at LMU University Hospital in Munich, Germany, as she shares her insights on the key developments for breast cancer treatment that emerged at ESMO Breast Cancer 2022.

The European Society for Medical Oncology (ESMO) has released expert consensus statements on HER2-low breast cancer, a newly recognized and targetable subtype. These statements address biology, diagnosis, treatment, and clinical trial design, aiming to guide oncologists in managing HER2-low metastatic disease.

Samsung Bioepis Co. Ltd. announced that Health Canada has approved Ontruzant (also known as SB3), a biosimilar referencing Herceptin (Trastuzumab), for the treatment of adults with Early Breast Cancer (EBC), Metastatic Breast Cancer (MBC) and metastatic gastric cancer (MGC).

In the last 30 years or so there has been increased attention on the medical uses of cannabis and its constituent chemicals. Cannabis itself contains at least 60 active cannabinoids, one of which, cannabidiol (CBD)...

National Institute for Health and Care Excellence (NICE) recommends;Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies Technology appraisal guidance [TA786]Published: 27 April 2022.

Gilead Sciences announced statistically significant and clinically meaningful results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase III TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy

The Pan-Asian adapted ESMO guidelines provide region-specific recommendations for diagnosing, staging, and treating metastatic breast cancer (MBC). Developed by experts from 10 Asian oncology societies, these consensus statements aim to harmonize care across Asia while accounting for genetic, demographic, and access-related differences.